MetaBiom
Microbiome & Chronic Diseases

Evidence Based Medicine
Sign in

Anti–Saccharomyces cerevisiae antibodies {90000291}

Record Keys


Biotic:
Anti–Saccharomyces cerevisiae antibodies
Parent:[  ]
Queue:[  ]

Details


Initialisation date:
2022-03-28
Specification:

ASCA

Source:
[  ]

Meta Information


Structural Type:[  ]
Functional Type:[  ]
Function:[  ]

Notes:


[  ]

References Notes


[  ]

Shared Reference Notes


  • [1.1
    - anti–Saccharomyces cerevisiae antibodies (ASCA) have been associated with CD.
    - ASCA detect S. cerevisiae mannan, a cell wall carbohydrate that is common to most fungi. Thus, the specificity of ASCA for Saccharomyces is not clear, since other common fungi, including Candida albicans, have abundant mannan in their cell walls.
    - Increases in both ASCA IgG and IgA are commonly observed in patients diagnosed with CD.
    - The ASCA IgA and IgG positive rate is over 50% in patients with CD and less than 5% in patients with non-IBD colitis or healthy controls.
    - In pediatric patients with CD, ASCA positivity has been associated with older children (>10 years), small bowel disease, and long-term risk of surgery.
    - In adults, ASCA has been linked to increases in disease severity, location, and age, with ASCA-positive patients more likely to have severe and complicated disease.
    - A recent study of pediatric patients in Australia noted that ASCA positivity correlated with increases and decreases in several specific bacteria, further suggesting that ASCA may be associated with specific subtypes of disease and that this may be reflected in the microbiome as well.
    - ASCA IgA was observed to be the most predictive marker of a future diagnosis of CD and was predictive as much as 5 years before diagnosis,

Common References